These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 31498109)

  • 1. Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study.
    Scarsi KK; Cramer YS; Rosenkranz SL; Aweeka F; Berzins B; Coombs RW; Coughlin K; Moran LE; Zorrilla CD; Akelo V; Aziz M; Friedman RK; Gingrich D; Swaminathan S; Godfrey C; Cohn SE;
    Lancet HIV; 2019 Sep; 6(9):e601-e612. PubMed ID: 31498109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptives.
    Haas DW; Cramer YS; Godfrey C; Rosenkranz SL; Aweeka F; Berzins B; Coombs R; Coughlin K; Moran LE; Gingrich D; Zorrilla CD; Baker P; Cohn SE; Scarsi KK;
    Pharmacogenet Genomics; 2020 Apr; 30(3):45-53. PubMed ID: 32106141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions between etonogestrel-releasing contraceptive implant and 3 antiretroviral regimens.
    Kreitchmann R; Stek A; Best BM; Capparelli E; Wang J; Shapiro D; Chakhtoura N; Mirochnick M; Eke AC;
    Contraception; 2022 Jan; 105():67-74. PubMed ID: 34407424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial of double vs single-dose etonogestrel implant to overcome the interaction with efavirenz-based antiretroviral therapy.
    Chappell CA; Lamorde M; Nakalema S; Kyohairwe I; Byakika-Kibwika P; Meyn LA; Pham MM; Scarsi KK
    Am J Obstet Gynecol; 2024 Aug; 231(2):242.e1-242.e9. PubMed ID: 38458408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.
    Daar ES; Tierney C; Fischl MA; Sax PE; Mollan K; Budhathoki C; Godfrey C; Jahed NC; Myers L; Katzenstein D; Farajallah A; Rooney JF; Pappa KA; Woodward WC; Patterson K; Bolivar H; Benson CA; Collier AC;
    Ann Intern Med; 2011 Apr; 154(7):445-56. PubMed ID: 21320923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients.
    Röshammar D; Simonsson US; Ekvall H; Flamholc L; Ormaasen V; Vesterbacka J; Wallmark E; Ashton M; Gisslén M
    J Pharmacokinet Pharmacodyn; 2011 Dec; 38(6):727-42. PubMed ID: 21964996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial.
    João EC; Morrison RL; Shapiro DE; Chakhtoura N; Gouvèa MIS; de Lourdes B Teixeira M; Fuller TL; Mmbaga BT; Ngocho JS; Njau BN; Violari A; Mathiba R; Essack Z; Pilotto JHS; Moreira LF; Rolon MJ; Cahn P; Prommas S; Cressey TR; Chokephaibulkit K; Werarak P; Laimon L; Hennessy R; Frenkel LM; Anthony P; Best BM; Siberry GK; Mirochnick M
    Lancet HIV; 2020 May; 7(5):e322-e331. PubMed ID: 32386720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efavirenz but Not Atazanavir/Ritonavir Significantly Reduces Atovaquone Concentrations in HIV-Infected Subjects.
    Calderón MM; Penzak SR; Pau AK; Kumar P; McManus M; Alfaro RM; Kovacs JA
    Clin Infect Dis; 2016 Apr; 62(8):1036-1042. PubMed ID: 26797214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART.
    Neary M; Chappell CA; Scarsi KK; Nakalema S; Matovu J; Achilles SL; Chen BA; Siccardi M; Owen A; Lamorde M
    J Antimicrob Chemother; 2019 Oct; 74(10):3003-3010. PubMed ID: 31299074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial.
    Bunupuradah T; Kiertiburanakul S; Avihingsanon A; Chetchotisakd P; Techapornroong M; Leerattanapetch N; Kantipong P; Bowonwatanuwong C; Banchongkit S; Klinbuayaem V; Mekviwattanawong S; Nimitvilai S; Jirajariyavej S; Prasithsirikul W; Munsakul W; Bhakeecheep S; Chaivooth S; Phanuphak P; Cooper DA; Apornpong T; Kerr SJ; Emery S; Ruxrungtham K;
    Lancet HIV; 2016 Aug; 3(8):e343-e350. PubMed ID: 27470026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy.
    Chappell CA; Lamorde M; Nakalema S; Chen BA; Mackline H; Riddler SA; Cohn SE; Darin KM; Achilles SL; Scarsi KK
    AIDS; 2017 Sep; 31(14):1965-1972. PubMed ID: 28692531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients.
    King JR; Yogev R; Jean-Philippe P; Graham B; Wiznia A; Britto P; Carey V; Hazra R; Acosta EP;
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4290-4. PubMed ID: 21670182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.
    Dlamini JN; Hu Z; Somaroo H; Highbarger HC; Follmann DA; Dewar RL; Pau AK
    Pharmacotherapy; 2011 Feb; 31(2):158-63. PubMed ID: 21275494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women.
    Cohan D; Natureeba P; Koss CA; Plenty A; Luwedde F; Mwesigwa J; Ades V; Charlebois ED; Gandhi M; Clark TD; Nzarubara B; Achan J; Ruel T; Kamya MR; Havlir DV
    AIDS; 2015 Jan; 29(2):183-91. PubMed ID: 25426808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
    Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
    Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial).
    Miro JM; Manzardo C; Ferrer E; Loncà M; Guardo AC; Podzamczer D; Domingo P; Curran A; Clotet B; Cruceta A; Lozano F; Pérez I; Plana M; Gatell JM;
    J Acquir Immune Defic Syndr; 2015 Jun; 69(2):206-15. PubMed ID: 25831464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks.
    Scarsi KK; Darin KM; Nakalema S; Back DJ; Byakika-Kibwika P; Else LJ; Dilly Penchala S; Buzibye A; Cohn SE; Merry C; Lamorde M
    Clin Infect Dis; 2016 Mar; 62(6):675-682. PubMed ID: 26646680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
    Orrell C; Hagins DP; Belonosova E; Porteiro N; Walmsley S; Falcó V; Man CY; Aylott A; Buchanan AM; Wynne B; Vavro C; Aboud M; Smith KY;
    Lancet HIV; 2017 Dec; 4(12):e536-e546. PubMed ID: 28729158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
    Bifano M; Hwang C; Oosterhuis B; Hartstra J; Grasela D; Tiessen R; Velinova-Donga M; Kandoussi H; Sevinsky H; Bertz R
    Antivir Ther; 2013; 18(7):931-40. PubMed ID: 23963204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A validated method for simultaneous quantification of four antiretrovirals in dried blood spot and plasma using LC-MS/MS: Application to efavirenz therapeutic drug monitoring in pregnant patients.
    Ludna Duarte M; Mikaelle Brandão Silva A; Wellithom Viturino da Silva J; Pereira Santana D; Victor de Castro W; Cláudio Arraes de Alencar L; César Galindo Bedor D; Bastos Leal L
    Clin Biochem; 2024 May; 127-128():110765. PubMed ID: 38649089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.